Larch Arabinogalactan From Larix Laricina And Larix Occidentalis Has Been Approved By The Australian Authorities

摘要

The Australian Authorities announced on July 8th that Larch arabinogalactan is now approved as a therapeutically active ingredient for oral use. Three requirements have to be met for approval all of which are fulfilled by Lonza's active ingredient: the ingredient arabinogalactan (Larix) is derived from Larix larcinia or Larix occidentalis; the concentration of polysaccharides in the ingredient arabinogalactan (Larix) is greater than or equal to 85%; and the maximum recommended daily dose of the ingredient arabinogalactan (Larix) is not to exceed 15 grams.